Table of Contents
Hepatitis Research and Treatment
Volume 2010, Article ID 702748, 6 pages
Clinical Study

Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C

1Department of Gastroenterology, Tokai University School of Medicine, Isehara 259-1193, Japan
2Department of Gastroenterology, Tokai University Hachioji Hospital, Tokyo 192-0032, Japan
3Department of Gastroenterology, Tokai University Tokyo Hospital, Tokyo 151-0053, Japan
4Department of Gastroenterology, Tokai University Oiso Hospital, Oiso 259-0198, Japan
5Ikegami General Hospital, Tokyo 146-8531, Japan
6Isehara Kyodo Hospital, Isehara 259-1132, Japan
7Japan Medical Alliance Ebina General Hospital, Ebina 243-0433, Japan
8Tomei-Atsugi Hospital, Atsugi 243-8571, Japan
9Hiratsuka City Hospital, Hiratsuka 254-0065, Japan
10Department of Community Health, Tokai University School of Medicine, Isehara 259-1193, Japan

Received 3 May 2010; Revised 26 June 2010; Accepted 29 June 2010

Academic Editor: Emmet B. Keeffe

Copyright © 2010 Makoto Numata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


To clarify the impact of adherence, we treated 122 genotype 1 high viral titer chronic hepatitis C patients with pegylated interferon (peg-IFN) and ribavirin for 48 weeks at nine referral hospitals, and evaluated the prognostic factors with a focus on the adherence to the treatment. This study included 68 (55.7%) treatment-naïve patients and 54 (44.3%) patients who did not respond to the previous treatment. Multivariate analysis revealed adherence to peg-IFN and ribavirin as the only significant predictor. Sustained virological response (SVR) rate was 72.2%, 19.0%, and 27.3% in patients given ≥80%, 60%–80%, and <60% dose peg-IFN, respectively, and was 68.6%, 41.2%, and 5.3% in those given ≥80%, 60%–80%, and <60% dose ribavirin, respectively. SVR rate sharply fell when exposure to peg-IFN was below 80% whereas it decreased in a stepwise manner as for ribavirin. Therefore, ≥80% of peg-IFN and as much as possible dose of ribavirin are desired to achieve SVR in the treatment of genotype 1 high viral titer chronic hepatitis C.